Cargando…
Use of Dalfampridine in a Young Child with Episodic Ataxia Type 2
Episodic ataxia type 2 (EA2) is a rare autosomal dominant disorder associated with mutations of the CACNA1A gene.( 1 ) Because there is no curative therapy available, EA2 is typically managed symptomatically. First line treatment has typically been with acetazolamide.( 2 ) Dalfampridine has also bee...
Autores principales: | Malamud, Emily, Otallah, Scott I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811424/ https://www.ncbi.nlm.nih.gov/pubmed/35127965 http://dx.doi.org/10.1177/2329048X221075447 |
Ejemplares similares
-
SCN2A- Associated Episodic and Persistent Ataxia
with Cerebellar Atrophy: A Case Report
por: Murray, Maeve, et al.
Publicado: (2023) -
A Massive Overdose of Dalfampridine
por: Fil, Laura J., et al.
Publicado: (2015) -
Clarification of Dalfampridine Labeled Indications
por: Rabinowicz, Adrian L., et al.
Publicado: (2012) -
Guillain-Barré Syndrome After COVID-19 Vaccination in an Adolescent
por: Malamud, Emily, et al.
Publicado: (2022) -
“Guillain-Barré Syndrome After COVID-19 Vaccination in an Adolescent” [Pediatric Neurology, Volume 126, January 2022, Pages 9-10]
por: Malamud, Emily, et al.
Publicado: (2022)